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rch 26, 2013.he aim of the study was to develop and validate a tool for predicting risk of contrast-induced nephropathy (CIN) in
patients undergoing contemporary percutaneous coronary intervention (PCI).Background CIN is a common complication of PCI and is associated with adverse short- and long-term outcomes. Previously
described risk scores for predicting CIN either have modest discrimination or include procedural variables and thus
cannot be applied for pre-procedural risk stratiﬁcation.Methods Random forestmodels were developed using 46 pre-procedural clinical and laboratory variables to estimate the risk of
CIN in patients undergoing PCI. The 15most inﬂuential variableswere selected for inclusion in a reducedmodel. Model
performance estimating risk of CIN and new requirement for dialysis (NRD)was evaluated in an independent validation
data set using area under the receiver-operating characteristic curve (AUC), with net reclassiﬁcation improvement used
to compare full and reduced model CIN prediction after grouping in low-, intermediate-, and high-risk categories.Results Our study cohort comprised 68,573 PCI procedures performed at 46 hospitals between January 2010 and June
2012 in Michigan, of which 48,001 (70%) were randomly selected for training the models and 20,572 (30%) for
validation. The models demonstrated excellent calibration and discrimination for both endpoints (CIN AUC for full
model 0.85 and for reduced model 0.84, p for difference <0.01; NRD AUC for both models 0.88, p for difference ¼
0.82; net reclassiﬁcation improvement for CIN 2.92%, p ¼ 0.06).Conclusions The risk of CIN and NRD among patients undergoing PCI can be reliably calculated using a novel easy-to-use
computational tool (https://bmc2.org/calculators/cin). This risk prediction algorithm may prove useful for
both bedside clinical decision making and risk adjustment for assessment of quality. (J Am Coll Cardiol
2013;61:2242–8) ª 2013 by the American College of Cardiology FoundationContrast-induced nephropathy (CIN) is a common
complication among patients undergoing invasive cardiac
procedures and is associated with increased morbidity,
mortality, and healthcare expense (1,2). Multiple strategies
have been demonstrated to be successful for prophylaxis of
CIN, including adequate hydration, minimization of
contrast dose, and the use of iso-osmolar or certain lowedicine, Division of Cardiovascular Medicine,
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3; revised manuscript received March 12, 2013,osmolar contrast media (3–6). Prospectively identifying
patients at risk of CIN would be of immense value in tar-
geting prophylactic therapy to those at high risk. Current
guidelines recommend use of prophylactic therapy in
patients with altered renal function, although this approach
has limited sensitivity and speciﬁcity (7–10).
For better risk stratiﬁcation of patients, efforts have been
made to develop risk prediction tools or risk scores to
identify patients most likely to develop CIN (11,12). The
most commonly used risk score was described by Mehran
et al. (13) and is based on the presence of 8 factors (hypo-
tension, use of intra-aortic balloon pump, congestive heart
failure, chronic kidney disease, diabetes, age >75 years,
anemia, and volume of contrast). This model cannot be used
for pre-procedure identiﬁcation of at-risk patients because
it incorporates procedural variables for risk prediction.
To overcome this limitation, Tsai et al. (14) recently
reported a risk score derived from the American College
of Cardiology National Cardiovascular Data Registry
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AKI = acute kidney injury
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NRD = nephropathy requiring
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2243percutaneous coronary intervention (PCI) registry that only
uses pre-procedure variables, but this model has modest
discrimination and may not be appropriate for patient-level
decision making.
Traditionally, simple risk scores have been favored to
facilitate bedside calculations, although this can compromise
the accuracy of prediction (15). The widespread use of
computers in medical care has opened up the possibility of
bedside application of more complex tools that leverage
developments in statistical science and facilitate use of algo-
rithms that cannot be easily converted into risk scores (16,17).
The goal of our work was to use such methods to develop
a highly accurate model for prediction of CIN using pre-
procedural variables that are routinely collected in patients
undergoing PCI while retaining the advantages of bedside
applicability.
Methods
Data for development and validation of a new CIN model
were derived from the Blue Cross Blue Shield of Michigan
Cardiovascular Consortium (BMC2), a quality improve-
ment collaborative that tracks the inpatient outcome of
consecutive patients undergoing PCI at all nonfederal
hospitals in the state of Michigan. The details of the BMC2
and its data collection and auditing process have been
described previously (18,19). Procedural data on all
consecutive patients undergoing PCI at participating
hospitals were collected using standardized data collection
forms. Baseline data included clinical, demographic, proce-
dural, and angiographic characteristics; medications used
before, during, and after the procedure; and in-hospital
outcomes. All data elements were prospectively deﬁned,
and the protocol was approved by local institutional review
boards at each of the participating hospitals. In addition to
a random audit of 2% of all cases, medical records of all
patients undergoing multiple procedures or coronary artery
bypass grafting and patients who died in the hospital were
reviewed routinely to ensure data accuracy.
The study population for this analysis included all
consecutive patients who underwent PCI between January 1,
2010, and June 30, 2012. Patients who were already on
dialysis at the time of the procedure or those with missing
serum creatinine levels pre- or post-procedure were excluded
from outcome analysis. The type of contrast media and
hydration protocols used were as per operator preference
guided by institutional policy and practice.
Study endpoints. The primary endpoint for our study was
CIN, which was deﬁned as impairment in renal function
resulting in 0.5 mg/dl absolute increase in serum creatinine
level from baseline (16). Baseline creatinine level was collected
within a month of the procedure. Among patients who had
multiple assessments of serum creatinine in the 30 days
before the procedure, the value closest to the time of the
procedure was considered the baseline value. Peak creatinine
level was deﬁned as the highest value of creatinine in theweek following the procedure and
was ascertained per local clinical
practice. Peak creatinine level was
collected at least 1 day post-
procedure but varied depending
on length of stay.
The secondary endpoint for the
study was nephropathy requiring
dialysis (NRD), which was de-
ﬁned as new, unplanned need for
dialysis during the hospitalization
due to worsening of renal func-
tion after PCI.
Model development. The study
cohort was divided randomly
into training and validation data sets, with 70% of proce-
dures assigned to training and the remaining 30% used for
validation. A random forest regression model was trained
for predicting CIN using 46 baseline clinical variables,
including pre-procedural medications, with missing predic-
tors imputed to be the overall median for continuous values
and mode for categorical variables. Random forest is an
ensemble classiﬁcation method that determines a consensus
prediction for each observation by averaging the results of
many individual recursive partitioning tree models. Each of
the individual trees are ﬁtted to a randomly selected subset
of the observations and use a random subset of the available
predictors at each node as candidates for splitting. Random
forests have been shown to have good predictive value and
are generally robust to issues of overﬁtting, rendering them
particularly useful for evaluating a large number of possible
predictors and exploiting potential interactions between
predictors and their relationship with the outcome (20). The
CIN outcome was entered as a continuous variable coded as
1 in patients developing CIN and 0 for those not meeting
the criteria to facilitate regression rather than classiﬁcation
modeling; estimated means (leaf node probabilities of CIN)
assigned to a given observation were then aggregated in the
ensemble. To facilitate the development of an easy-to-use
bedside tool, a reduced model was also trained using only
the 15 most important predictors as assessed in the full
model by the incremental decrease in node impurity
(residual sum of squares) associated with splitting on the
predictor averaged over all trees in the ensemble.
Model validation. The full and reduced models were
evaluated in terms of discrimination and predictive power in
the validation data set. Random forest estimates for obser-
vations in the validation data set were scaled so that the
overall predicted CIN rate for the validation sample matched
the overall CIN rate observed in the training data set.
Overall diagnostic accuracy was estimated using the area
under the receiver-operating curve (AUC) assessed via the
trapezoidal method, with standard error estimation using the
method of DeLong et al. (21). To evaluate bias or non-
constancy of variance across different levels of predicted risk,
patients in the validation data set were grouped by predicted
Table 1 Patient/Procedural Characteristics Included in Full Model
Pre-Procedural
Therapy
Clinical
History
Patient
Characteristics
Patient
Presentation
Pre-Procedural
Laboratory
Assessments
Beta-blockers Gastrointestinal bleeding Race: black or African American PCI indication Creatine kinase-MB
Antianginal medication
within 2 weeks
Heparin-induced
thrombocytopenia
Sex PCI status Creatinine
Calcium channel blockers Surgery within 7 days before
procedure
Current/recent smoker
(within 1 yr)
CAD presentation Hemoglobin
Long-acting nitrates Hypertension Age, yrs Pre-operative evaluation before
noncardiac surgery
Troponin I
Other antianginal agent Cerebrovascular disease Weight, kg Pre-PCI left ventricular ejection
fraction
Troponin T
Ranolazine Prior heart failure Height, cm Cardiogenic shock
Thrombolytics Prior myocardial infarction Heart failure within 2 weeks
Pre-procedural vasopressors Peripheral arterial disease Cardiac arrest within 24 h
Prior PCI
Dyslipidemia
Family history of premature CAD
History of atrial ﬁbrillation
History of cardiac transplant
Prior valve surgery
Cardiomyopathy or left
ventricular systolic dysfunction
Chronic lung disease
Diabetes mellitus/diabetes
therapy
Prior CABG
Prior ICD implant
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; ICD ¼ implantable cardioverter-deﬁbrillator; PCI ¼ percutaneous coronary intervention.
Table 2
Patient/Procedural Characteristics Selected for
Reduced Model
Patient presentation
PCI indication
PCI status
CAD presentation
Cardiogenic shock
Heart failure within 2 weeks
Pre-PCI left ventricular ejection fraction
Clinical history
Diabetes mellitus/diabetes therapy
Patient characteristics
Age, yrs
Weight, kg
Height, cm
Pre-procedural laboratory assessments
Creatine kinase-MB
Serum creatinine
Hemoglobin
Troponin I
Troponin T
Abbreviations as in Table 1.
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2244CIN risk level; for each of these groups, the incidence of
CIN was calculated and plotted against mean predicted risk.
The net reclassiﬁcation improvement (NRI) statistic was
used to compare model performance, with predicted risk
values grouped into 3 levels: low-, medium-, and high-risk
patients; p values and CIs were obtained through boot-
strapping (22,23). The additional utility of the models for
discrimination of risk of NRD post-procedurally was eval-
uated in the validation data set through assessment of AUC.
The potential application of the tool for calculating pre-
dicted risk and its use in guiding the decision to administer
prophylactic therapy such as pre-procedure hydration was
compared with the currently recommended strategy of using
glomerular ﬁltration rate (GFR)–based selection by plotting
the percentage of patients developing CIN to the percentage
of all patients who would be selected for prophylaxis by each
strategy graphically over the entire range of potential cutoff
values (7,10). Patients who would not routinely be consid-
ered for prophylaxis, such as those with ST-segment
elevation myocardial infarction, cardiogenic shock, or
cardiac arrest, were excluded from this analysis.
All analysis was performed in R version 2.14.1 using freely
distributed statistical packages (24,25).
Results
Our study cohort comprised 68,573 of the 81,218 proce-
dures (84%) performed across Michigan between January2010 through June 2012. Of the 12,645 procedures (16%)
that were excluded from the analysis, 1,897 patients were
already on dialysis at the time of the procedure and the
remainder had missing serum creatinine values before
(n ¼ 1,903) or following the PCI procedure (n ¼ 8,655).
Table 3 Distribution of Reduced Model Covariates by CIN in Training Data Set
Characteristic Training Dataset Patients Without CIN Training Dataset Patients With CIN p Value
Age of patient at the time of care, yrs 64.8  12.1 (46,758) 70.3  12.3 (1,243) <0.001
Weight, kg 89.4  21.3 (46,758) 88.4  23.2 (1,243) 0.137
Height, cm 171.1  10.6 (46,758) 168.2  10.8 (1,243) <0.001
CAD presentation
Symptom unlikely to be ischemic 1,099/46,737 (2.4%) 20/1,243 (1.6%) 0.087
No symptom, no angina 3,359/46,737 (7.2%) 56/1,243 (4.5%) <0.001
Stable angina 8,034/46,737 (17.2%) 47/1,243 (3.8%) <0.001
Unstable angina 17,941/46,737 (38%) 295/1,243 (24%) <0.001
Non–STEMI 9,263/46,737 (20%) 398/1,243 (32%) <0.001
STEMI or equivalent 7,041/46,737 (15%) 427/1,243 (34%) <0.001
PCI indication
Immediate PCI for STEMI 6,233/46,746 (13%) 354/1,242 (29%) <0.001
PCI for STEMI (unstable, >12 h from symptom onset) 311/46,746 (0.67%) 47/1,242 (3.78%) <0.001
PCI for STEMI (stable, >12 h from symptom onset) 173/46,746 (0.37%) 12/1,242 (0.97%) <0.001
PCI for STEMI (stable after successful full-dose thrombolysis) 189/46,746 (0.40%) 6/1,242 (0.48%) 0.667
Rescue PCI for STEMI (after failed full-dose lytics) 262/46,746 (0.56%) 14/1,242 (1.13%) 0.009
PCI for high-risk non-STEMI or unstable angina 22,725/46,746 (49%) 624/1,242 (50%) 0.257
Staged PCI 3,028/46,746 (6.5%) 33/1,242 (2.7%) <0.001
Other 13,825/46,746 (30%) 152/1,242 (12%) <0.001
PCI status
Elective 18,717/46,723 (40%) 147/1,243 (12%) <0.001
Urgent 20,651/46,723 (44%) 610/1,243 (49%) <0.001
Emergency 7,302/46,723 (16%) 460/1,243 (37%) <0.001
Salvage 53/46,723 (0.11%) 26/1,243 (2.09%) <0.001
Heart failure within 2 weeks 4,418/46,737 (9.5%) 498/1,241 (40.1%) <0.001
Pre-PCI left ventricular ejection fraction 52.1  12.5 (36,153) 43.1  16.4 (858) <0.001
Cardiogenic shock within 24 h or start of PCI 883/46,707 (1.9%) 230/1,243 (18.5%) <0.001
Pre-procedural laboratory assessments
CK-MB 27.1  66.2 (9,062) 33.3  54.9 (369) 0.035
CK not applicable/available 33,232/46,758 (71%) 742/1,243 (60%) <0.001
Creatinine, mg/dl 1.0  0.4 (46,758) 1.5  0.9 (1,243) <0.001
Hemoglobin, g/l 13.5  1.9 (46,049) 12.0  2.2 (1,227) <0.001
Troponin I 4.3  21.1 (20,011) 9.8  35.8 (831) <0.001
Troponin l not drawn 26,726/46,758 (57%) 412/1,243 (33%) <0.001
Troponin T 0.7  4.1 (4,082) 2.4  9.9 (129) 0.060
Troponin T not drawn 42,657/46,758 (91%) 1,114/1,243 (90%) 0.048
Values are mean  SD (N) or n/N (%).
CIN ¼ contrast-induced nephropathy; CK ¼ creatine kinase; STEMI ¼ ST-segment elevation myocardial infarction; other abbreviations as in Table 1.
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2245The training dataset consisted of 48,001 PCI procedures,
of which 1,243 (2.59%) resulted in CIN; the validation data
set consisted of 20,572 procedures, of which 505 (2.45%)
resulted in CIN. NRD developed in 169 of the patients
(0.35%) in the development cohort and 66 of patients
(0.32%) in the validation cohort. All 46 baseline variables
presented in Table 1 were included in the full random forest
model. The training and validation datasets were similar in
terms of baseline covariates (Online Table 1). The 15 vari-
ables with the largest model determined importance are
listed in Table 2, and Table 3 provides their distribution in
training dataset patients both with and without CIN. All but
one of these variables, patient weight, were univariately
associated with CIN. This set of predictors was used to ﬁt
the reduced random forest model that is available for use at
https://bmc2.org/calculators/cin.
When evaluated in the validation dataset, both models
provided good discrimination for CIN, with the fullmodel having a small but statistically signiﬁcant advantage
in AUC (full model 0.852, 95% CI: 0.835 to 0.869;
reduced model 0.839, 95% CI: 0.821 to 0.857; p for
difference ¼ 0.001). Similarly, both models had good
discrimination for NRD, but the full and reduced models
performed equally well in terms of AUC for this outcome
(full model 0.875, 95% CI: 0.819 to 0.931; reduced model
0.875, 95% CI: 0.823 to 0.931; p for difference ¼ 0.815).
Both models demonstrated excellent calibration (Fig. 1)
with good concordance between observed and predicted
risk of CIN.
The full and reduced model predictions were also grouped
into low-risk (<1%), intermediate-risk (1% to 7%), and high-
risk (>7%) categories, and the number of patients along with
the observed CIN rate in each group is presented in Table 4.
The NRI statistic for the full model relative to the reduced
model for these categories was not statistically signiﬁcant
(NRI 2.92%; p ¼ 0.062; 95% CI: 0.14% to 6.03%).
Figure 1
Plot of Observed Versus Predicted Risk of
Renal Complications Across the Continuum of
Predicted Risk
(A) The observed versus predicted rates of contrast-induced nephropathy (CIN) for
the full model. (B) The observed versus predicted risk of CIN for the reduced
model.
Table 4 Model Comparison by Risk Category
Predicted Risk
PCI Procedure,
n (%)
CIN,
n (% of CIN)
CIN Rate,
%
Full model
Low (<1%) 12,154 (59.1) 56 (11.1) 0.46
Intermediate (1%-7%) 6,324 (30.7) 164 (32.5) 2.59
High (>7%) 2,094 (10.2) 285 (56.4) 13.61
Reduced model
Low (<1%) 12,471 (60.6) 64 (12.7) 0.51
Intermediate (1%-7%) 6,014 (29.2) 170 (33.6) 2.83
High (>7%) 2,087 (10.1) 271 (53.7) 12.99
Abbreviations as in Tables 1 and 3.
Figure 2
Percentage of Patients Developing CIN Versus
Percentage of All Patients Who Would Be Selected
for Prophylaxis at Different Levels of Estimated GFR
or Estimated Risk Using the Full or Reduced Model
The vertical line corresponds to the patients who would be selected if the currently
recommended glomerular ﬁltration rate (GFR) threshold of <60 ml/min/1.73 m2
was used. The same number of patients would be selected by using a predicted
risk threshold of >2% using the simpliﬁed model but would capture a larger
proportion of patients who go on to develop CIN (72% vs. 62% using GFR-based
selection). Abbreviation as in Figure 1.
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2246Figure 2 compares the performance of the full and
reduced models with a GFR-based strategy for selection of
patients for prophylactic therapy and demonstrates the
advantage of using the full or the reduced model over the
contemporary practice of using a GFR-based threshold. If
a decision were made to select 10% of the highest-risk
patients, this highest-risk cohort would contain 52% of the
patients who would potentially develop CIN using the full
model, compared with 50% if the reduced model were used
versus 41% for a GFR-based strategy. Using the currentlyrecommended cutoff of GFR <60 ml/min/1.73 m2, and
after excluding the high-risk patients, 23.5% of the pop-
ulation would be selected for hydration; this would capture
62% of the patients who would develop CIN. Assuming the
same number of patients were to be selected for pre-
treatment, this would correspond to a predicted risk of
>2.1% using the full model and a risk of >2.0% using the
reduced model and would capture 75% and 72% of the
patients who develop CIN, respectively.
Discussion
The key ﬁnding of our study was that standard clinical and
laboratory variables that are routinely collected in patients
JACC Vol. 61, No. 22, 2013 Gurm et al.
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2247undergoing PCI can be easily and reliably used to predict the
risk of CIN and NRD using a novel computational tool.
The robust discrimination and calibration of this method,
combined with the ease of use for simpliﬁed bedside
prediction, makes this model an easy tool to apply clinically.
Use of risk stratiﬁcation has been advocated for both
patient-level decision making (for guiding informed consent
and therapeutic decision making) and risk adjustment for
assessment of quality of care. Our work has several key
advantages that make it particularly suitable for these
purposes. First and foremost, our model has a much higher
discrimination than has been traditionally reported formodels
or risk scores that have been developed to predict CIN. As an
example, theMehran model has a C-statistic of 0.67, whereas
theNationalCardiovascularData Registry acute kidney injury
(AKI) model has a C-statistic of 0.72 (13,14). Second, our
model should be generalizable to routine clinical practice
because it was developed and validated on all consecutive
patients treated in Michigan and reﬂects contemporary
practice across multiple institutions and operators. Third, the
model was based only on pre-procedure variables and thus can
be used for risk stratiﬁcation before the procedure so that
alternate therapeutic strategies could be explored and
prophylactic strategies such as hydration or novel therapies
that are currently being investigated could potentially be
applied for patients who are deemed to be at high risk of
complications. Finally, the model also provides highly accu-
rate prediction for the risk of NRD, a complication that both
physicians and patients are most keen to avoid.
Our model differs from traditional risk scores in that it
requires a computer for calculation rather than something
that can be estimated as a bedside arithmetic risk score.
Although simple scores have been favored in the past, this
approach may sacriﬁce accuracy and have the potential to
mislead rather than truly inform clinical practice (15).
Further, the widespread use of electronic medical records
and bedside use of computers in medicine has made it
possible to embed complex algorithms into clinical work-
ﬂow, and the widespread use of smart devices makes it
practical to use these models at the bedside.
We developed 2 different models, with the full model
providing a slightly greater discrimination, but this did not
translate into a signiﬁcant improvement in NRI. This would
suggest that the abbreviated model developed for bedside use
is almost as good as the full model for clinical decisionmaking,
although the full model would be preferable for use if it could
be achieved without undue burden on clinicians.We envision
that initially the simpler model would be used for routine
clinical decisionmaking, whereas the detailedmodel would be
used for quality assessment and benchmarking across insti-
tutions and operators. We prefer the use of the full model for
these purposes because the presence of minor risk factors such
as atrial ﬁbrillation or PCI after recent surgery could vary
considerably across institutions and not accounting for the
variation in these factors could result in misclassiﬁcation of
observed to expected ratios at an institutional level. It istechnically easy to embed this full model into electronic
medical records and speciﬁcally into the templates that are
used for documentation of the initial history and physical
assessment of a patient being evaluated for PCI. Having such
availability would help patients and physicians make better
informed decisions but would require greater input from the
vendors of electronic medical record systems.
The clinical utility of risk scores beyond research and
patient consent remains unexplored. We have suggested one
possible use, whereby catheterization laboratories can
determine policies targeted to speciﬁc patient populations
based on their pre-procedure risk and therefore optimize
patient safety without an increase in space and personnel
utilization. It is, however, likely that as clinicians use this
tool in practice, other uses will emerge that will lead to
further optimization of patient care, as well as modiﬁcation
and reﬁnement of the prediction tool.
Study limitations. Like most observational studies, our
study ﬁndings must be evaluated with certain caveats. We
have used the term “CIN,” although the role of contrast
media in all patients who develop AKI after PCI remains
debatable. It is likely that AKI after PCI is multifactorial,
and it may be preferable to use terms that do not assume that
all renal dysfunction after PCI is secondary to contrast
media. However, regardless of the term used, our model
performed well and helps identify patients prone to develop
renal complications after PCI. Our risk model was derived
from a population in which serum creatinine ascertainment
was not standardized but was clinically driven. Only 1 post-
procedure creatinine value was available, and no follow-up
beyond the initial hospitalization was performed. No data
on the type and amount of hydration used were available,
and this likely varied across institutions. However, we believe
this makes our model more generalizable to routine clinical
care because it reﬂects ﬁndings from contemporary practice
across multiple institutions.Conclusions
We have developed a simple tool for accurately predicting
risk of CIN and NRD among patients undergoing PCI.
This risk prediction algorithm may prove useful for both
bedside clinical decision making and risk adjustment for
assessment of quality.
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